ArticleImmunity, inflammation and disease2021
CircZNF124 regulates cell proliferation, leucine uptake, migration and invasion by miR-199b-5p/SLC7A5 pathway in endometrial cancer.
Article in Immunity, inflammation and disease, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It carries an expression of concern. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 16 citations in OpenAlex.
- Glioma cells achieve malignant progression by fusion with macrophages to gain high SLC7A5 expression.Journal of neuro-oncology · 2025Article
- Curcumin as an Epigenetic Modulator: Suppression of Breast Cancer via the Hsa_circ_0001946/MiR-7-5p/Target Gene Axis.Medicina (Kaunas, Lithuania) · 2025Article
- CircABHD2 Inhibits Malignant Progression of Endometrial Cancer by Regulating NADMolecular biotechnology · 2025Article
- Advances in MiRNAs Involved in Endometrial Carcinoma.Combinatorial chemistry & high throughput screening · 2025Review
- Role of TPD52 in Endometrial Cancer: Impact on EMT and the PI3K/AKT and ERK/MAPK Signaling.Protein and peptide letters · 2025Article
- Circular RNAs and Cancers.Advances in experimental medicine and biology · 2025Review
- Leucine restriction ameliorates Fusobacterium nucleatum-driven malignant progression and radioresistance in nasopharyngeal carcinoma.Cell reports. Medicine · 2024Article
- circRNAs in Endometrial Cancer-A Promising Biomarker: State of the Art.International journal of molecular sciences · 2024Review
- Baicalein improves the chemoresistance of ovarian cancer through regulation of CirSLC7A6.Journal of ovarian research · 2023Article
- CircSMAD2 accelerates endometrial cancer cell proliferation and metastasis by regulating the miR-1277-5p/MFGE8 axis.Journal of gynecologic oncology · 2023Article
- Circular RNAs in endometrial carcinoma (Review).Oncology reports · 2022Review
- MicroRNAs in the Regulation of Solute Carrier Proteins Behind Xenobiotic and Nutrient Transport in Cells.Frontiers in molecular biosciences · 2022Review
- CircZNF124 regulates cell proliferation, leucine uptake, migration and invasion by miR-199b-5p/SLC7A5 pathway in endometrial cancer.Immunity, inflammation and disease · 2021Article
Corrections and comments
- Expression of concern
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRecent studies have revealed that circular RNA participates in endometrial carcinoma (EC) progression. Here we investigated the role of circRNA zinc finger protein 124 (circZNF124) in EC genesis and underlying mechanism.
methodsThe expression levels of circZNF124, microRNA-199b-5p (miR-199b-5p) and solute carrier family 7 member 5 (SLC7A5) were detected by quantitative real-time polymerase chain reaction. The expression of SLC7A5 and other indicated marker proteins was determined by western blot analysis. For functional assay, cell proliferation, leucine uptake and metastasis were investigated by total cell number, cell counting kit-8, cell colony formation, leucine uptake or transwell assay. The interaction between miR-199b-5p and circZNF124 or SLC7A5 was predicted by starbase online database, and identified by mechanism assays. The impact of circZNF124 absence on tumor growth in vivo was revealed by xenograft mouse model assay. Immunohistochemistry assay was implemented to detect the positive expression rate of nuclear proliferation marker (Ki67).
resultsCircZNF124 and SLC7A5 expression were significantly increased, while miR-199b-5p was decreased in EC tissues and cells compared with normal endometrial tissues or cells. CircZNF124 expression was closely associated with EC severity and lymph node metastasis. Additionally, circZNF124 depletion repressed cell proliferation, leucine uptake, migration and invasion in both HEC1A and Ishikawa cells. CircZNF124 regulated SLC7A5 expression by binding to miR-199b-5p. MiR-199b-5p inhibitors or SLC7A5 overexpression attenuated circZNF124 silencing-mediated EC malignant progression. Furthermore, SLC7A5 absence inhibited tumor growth in vivo.
conclusionCircZNF124 depletion inhibited EC cell malignancy by miR-199b-5p/SLC7A5 pathway, which demonstrated that circZNF124 had the potential as a therapeutic target for EC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.